These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29262899)

  • 21. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
    Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [In vitro synergistic effect of bortezomib and pirarubicin on proliferation and apoptosis of T cell lymphoma cell line Hut-78 cells].
    Qian ZZ; Wang HQ; Fu K; Ma YL; Hao XS
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):47-51. PubMed ID: 21429402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells.
    Cao Y; Qiu GQ; Wu HQ; Wang ZL; Lin Y; Wu W; Xie XB; Gu WY
    Mol Med Rep; 2016 Oct; 14(4):3469-75. PubMed ID: 27571872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.
    Liu Y; Cheng P; Zhao W; Zhu L; Sui J; Dai Y; Lai Y
    Leuk Res; 2022 Mar; 114():106785. PubMed ID: 35074616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
    Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
    Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined effects of bortezomib and daunorubicin on multiple myeloma cell KM3 in vitro.
    Ouyang GF; Lin MF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1468-71. PubMed ID: 20030928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
    Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells.
    Wang ZD; Wang RZ; Xia YZ; Kong LY; Yang L
    Chin J Nat Med; 2018 Jan; 16(1):20-28. PubMed ID: 29425587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of silencing survivin gene on sensitivity of myeloma cells to adriamycin].
    Li J; Zhao Y; Luo SK; Zhang DB; Huang BH
    Ai Zheng; 2006 Dec; 25(12):1488-92. PubMed ID: 17166372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.
    Dong XF; Song Q; Li LZ; Zhao CL; Wang LQ
    Neuro Endocrinol Lett; 2007 Dec; 28(6):775-80. PubMed ID: 18063935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells.
    Zhang W; Qiao L; Wang X; Senthilkumar R; Wang F; Chen B
    Int J Nanomedicine; 2015; 10():3275-89. PubMed ID: 25995634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.
    Salem K; McCormick ML; Wendlandt E; Zhan F; Goel A
    Redox Biol; 2015; 4():23-33. PubMed ID: 25485927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
    Tang JX; Chen Q; Li Q; He YH; Xiao D
    Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27.
    Li J; Zhang X; Shen J; Guo J; Wang X; Liu J
    Mol Med Rep; 2019 Sep; 20(3):2410-2418. PubMed ID: 31322176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
    Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
    Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-Aza-2'-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential.
    Łuczkowska K; Kulig P; Rusińska K; Baumert B; Machaliński B
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
    Wu X; Xia J; Zhang J; Zhu Y; Wu Y; Guo J; Chen S; Lei Q; Meng B; Kuang C; Feng X; He Y; Shen Y; Li X; Qiu L; Li G; Zhou W
    Br J Haematol; 2020 Jul; 190(1):52-66. PubMed ID: 32037523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomics and chemical library screens reveal a novel SCF
    Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
    Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.